VeredStearnsMD

Oncology • New York, NY

Breast Cancer, Hematologic Oncology

Professor of Oncology, Weill Cornell Medicine, Meyer Cancer Center

Join to view full profile

Dr. Stearns is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Stearns' full profile

Already have an account?

Office
420 East 70th Street
2nd Floor
New York, NY 10021
Phone+1 646-962-4053
Is this information wrong?

Summary

Dr. Vered Stearns is an oncologist in New York. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 25 years. She also speaks multiple languages, including Hebrew. She specializes in breast cancer and hematologic oncology and is experienced in breast cancer treatment and translational research. She has more than 100 publications and over 500 citings.

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1995 - 1997
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1992 - 1995
Rutgers Robert Wood Johnson Medical SchoolClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2023 - 2025
MD State Medical License 2002 - 2025
DC State Medical License 1996 - 2024
MI State Medical License 2001 - 2005

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 1997 Mar 01
Completed
Phase 2
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer Start of enrollment: 2003 Aug 11
Terminated
Phase 2
Aromatase Inhibitor Clinical Trial Start of enrollment: 2005 Jan 01
Unknown status
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 2
Study of PET Scans and Serotonin in Hot Flashes Treatment Start of enrollment: 2005 Oct 01
Terminated
Not Applicable
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 1
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Start of enrollment: 2006 Mar 01
Completed
Phase 2
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 2
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery Start of enrollment: 2006 May 01
Completed
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer Start of enrollment: 2008 May 01
Active, not recruiting
Phase 2
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer Start of enrollment: 2007 Aug 01
Completed
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Start of enrollment: 2011 Feb 01
Completed
Phase 2
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer Start of enrollment: 2011 Apr 21
Active, not recruiting
Phase 2
Pre-Operative Radiation and Veliparib for Breast Cancer Start of enrollment: 2013 Jul 22
Suspended
Phase 1
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer Start of enrollment: 2013 Jan 01
Completed
Phase 2
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Start of enrollment: 2013 Jun 11
Active, not recruiting
Not Applicable
POWER-remote Weight Loss Program in Early Stage Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Not Applicable
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database Start of enrollment: 2012 May 09
Active, not recruiting
IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins Start of enrollment: 2013 Sep 19
Completed
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins Start of enrollment: 2018 Jan 26
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11.
Vered Stearns, Opeyemi A Jegede, Victor Tsu-Shih Chang, Todd C Skaar, Jeffrey L Berenberg, Ranveer Nand, Atif Shafqat, Nisha Lassi Jacobs, William Luginbuhl, Paul Gilm...> ;Clinical Cancer Research. 2024 Apr 19
Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation.
Rattsev, I., Blackford, A., Hertz, D., Rae, J., Taylor, C., Stearns, V., Smith, K.> ;JAMIA Open. 2024 Apr 1
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.
Roussos Torres, E., Ho, W., Danilova, L., Tandurella, J., Leatherman, J., Rafie, C., Wang, C., Brufsky, A., LoRusso, P., Chung, V., Yuan, Y., Downs, M., O'Connor, A., ...> ;Nature Cancer. 2024 Feb 14
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang, Y., Gersch, C., Lehman, J., Henry, N., Rae, J., Hertz, D., Smith, K., Stearns, V.> ;Pharmacogenetics and Genomics. 2024 Feb 8
Exploring the links of skeletal muscle mitochondrial oxidative capacity, physical functionality, and mental well-being of cancer survivors.
Stephen G Gonsalves, Leorey N Saligan, Christopher M Bergeron, Philip R Lee, Kenneth W Fishbein, Richard G Spencer, Marta Zampino, Xinyi Sun, Jennifer Yeong-Shin Sheng...> ;Scientific Reports. 2024 Feb 1
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Filipa Lynce, Laura E Stevens, Zheqi Li, Jane E Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M Force, Tufia C Haddad, Naoto Ueno, Vered Stea...> ;Breast Cancer Research. 2024 Jan 31
Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.
Elizabeth Joyce, Xueting Tao, Vered Stearns, Daniel F Hayes, Anna Maria Storniolo, Kelley M Kidwell, N Lynn Henry> ;Breast Cancer Research and Treatment. 2024 Apr 1
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions.
Nada Lukkahatai, Jongmin Park, Hejingzi Monica Jia, Daniel Martin, Junxin Li, Jennifer Yeong-Shin Sheng, Jessica Gill, Leorey N Saligan, Vered Stearns, Michael Carducci> ;Biomedicines. 2023 Nov 16
3 citations
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, Lilja B Solnes, Rita Denbow, Vandana G Abramson, Lisa A Carey, Minetta C Liu, Mothaffar Rimawi, Jennifer Specht, Ann...> ;Journal of Nuclear Medicine. 2023 Nov 1
1 citations
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S Cogan, Vandana G Abramson, Judy C Boughey, Carla Falkson, Matthew P Goetz, James M Ford, William J Gradishar, Rache...> ;Breast Cancer Research and Treatment. 2023 Nov 1
2 citations
Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer.
Anna-Carson Rimer Uhelski, Amanda L Blackford, Jennifer Y Sheng, Claire Snyder, Jennifer Lehman, Kala Visvanathan, David Lim, Vered Stearns, Karen Lisa Smith> ;Journal of Cancer Survivorship. 2023 Jun 1
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
1 citations
The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting.
Natsuki Furukawa, Vered Stearns, Cesar A Santa-Maria, Aleksander S Popel> ;Expert Opinion on Therapeutic Targets. 2022 Dec 1
28 citations
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Olivia Pagani, Barbara A Walley, Gini F Fleming, Marco Colleoni, István Láng, Henry L Gomez, Carlo Tondini, Harold J Burstein, Matthew P Goetz, Eva M Ciruelos, Vered S...> ;Journal of Clinical Oncology. 2023 Mar 1
5 citations
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, d...
Amanda Vrselja, Ardian Latifi, Rodney J Baber, Bronwyn G A Stuckey, Michael G Walker, Vered Stearns, Martha Hickey, Susan R Davis> ;Lancet. 2022 Nov 12
1 citations
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer.
Neha Verma, Amanda L Blackford, Elissa Thorner, Jennifer Lehman, Claire Snyder, Vered Stearns, Karen Lisa Smith> ;Breast Cancer Research and Treatment. 2022 Dec 1
A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing.
Claire Snyder, Susan M Hannum, Sharon White, Amanda Montanari, Dara Ikejiani, Benjamin Smith, Amanda Blackford, Elissa Thorner, Katherine C Smith, Michael A Carducci, ...> ;Quality of Life Research. 2022 Aug 1
2 citations
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Daniel L Hertz, Julie A Douglas, Robert M Miller, Kelley M Kidwell, Christina L Gersch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F H...> ;Supportive Care in Cancer. 2022 Oct 1
4 citations
Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations.
Cesar A Santa-Maria, Maureen O'Donnell, Raquel Nunes, Jean L Wright, Vered Stearns> ;Journal of the National Comprehensive Cancer Network. 2022 Jul 1
2 citations
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A.
Rachel Raab, Nofisat Ismaila, Fabrice Andre, Vered Stearns, Kevin Kalinsky> ;JCO Oncology Practice. 2022 Sep 1
105 citations
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Fabrice Andre, Nofisat Ismaila, Kimberly H Allison, William E Barlow, Deborah E Collyar, Senthil Damodaran, N Lynn Henry, Komal Jhaveri, Kevin Kalinsky, Nicole M Kuder...> ;Journal of Clinical Oncology. 2022 Jun 1
4 citations
Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Elaine M Walsh, Neha Mangini, John Fetting, Deborah Armstrong, Isaac S Chan, Roisin M Connolly, Katie Fiallos, Jennifer Lehman, Raquel Nunes, Dana Petry, Jeffrey Reyno...> ;Clinical Breast Cancer. 2022 Jun 1
2 citations
Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer.
Mary Jo Fackler, Suzana Tulac, Neesha Venkatesan, Adam J Aslam, Timothy N de Guzman, Claudia Mercado-Rodriguez, Leslie M Cope, Bradley M Downs, Abdul Hussain Vali, Wan...> ;Cancer Research Communications. 2022 Jun 1
18 citations
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment.
Dimitrios N Sidiropoulos, Christine I Rafie, Julie K Jang, Sofi Castanon, Aaron G Baugh, Edgar Gonzalez, Brian J Christmas, Valerie H Narumi, Emily F Davis-Marcisak, G...> ;Cancer Immunology Research. 2022 May 3
12 citations
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation.
Karen Lisa Smith, Neha Verma, Amanda L Blackford, Jennifer Lehman, Kelly Westbrook, David Lim, John Fetting, Antonio C Wolff, Daniela Jelovac, Robert S Miller, Roisin ...> ;NPJ Breast Cancer. 2022 Apr 21
Join now to see all

Lectures

TAILORing Adjuvant Systemic Therapy for Breast Cancer
UT Health Science Center San Antonio, San Antonio, Texas - 12/6/2011

Press Mentions

Behind the Study: Weight Loss Strategies for Breast Cancer SurvivorsMarch 3rd, 2022
Battling Breast Cancer Year-Round: Why Breast Cancer Awareness Should Continue Even After OctoberOctober 30th, 2021
Inhibitor Drug Entinostat ‘Primes’ the Body to Better Respond to Anti-Cancer Treatment with ImmunotherapyAugust 19th, 2021
Join now to see all